MCID: HLC007
MIFTS: 59

Helicobacter Pylori Infection

Categories: Gastrointestinal diseases, Genetic diseases

Aliases & Classifications for Helicobacter Pylori Infection

MalaCards integrated aliases for Helicobacter Pylori Infection:

Name: Helicobacter Pylori Infection 56 71
Helicobacter Pylori Infection, Susceptibility to 56 29 6 39
H. Pylori Infection, Susceptibility to 56 13
Helicobacter Pylori Infections 42
H. Pylori Infection 56

Characteristics:

OMIM:

56
Inheritance:
not determined


Classifications:



External Ids:

OMIM 56 600263
MedGen 41 C1838332
UMLS 71 C0850666

Summaries for Helicobacter Pylori Infection

MedlinePlus : 42 Helicobacter pylori (H. pylori) is a type of bacteria that causes infection in the stomach. It is the main cause of peptic ulcers, and it can also cause gastritis and stomach cancer. About 30 to 40 percent of people in the United States get an H. pylori infection. Most people get it as a child. H. pylori usually does not cause symptoms. But it can break down the inner protective coating in some people's stomachs and cause inflammation. This can lead to gastritis or a peptic ulcer. Researchers aren't sure how H. pylori spreads. They think that it may spread by unclean food and water, or through contact with an infected person's saliva and other body fluids. A peptic ulcer causes a dull or burning pain in your stomach, especially when you have an empty stomach. It lasts for minutes to hours, and it may come and go for several days or weeks. It may also cause other symptoms, such as bloating, nausea, and weight loss. If you have the symptoms of a peptic ulcer, your health care provider will check to see whether you have H. pylori. There are blood, breath, and stool tests to check for H. pylori. In some cases, you may need an upper endoscopy, often with a biopsy. If you do have a peptic ulcer, the treatment is with a combination of antibiotics and acid-reducing medicines. You will need to be tested again after treatment to make sure the infection is gone. There is no vaccine for H. pylori. Since H. pylori might spread through unclean food and water, you might be able to prevent it if you Wash your hands after using the bathroom and before eating Eat properly prepared food Drink water from a clean, safe source NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Helicobacter Pylori Infection, also known as helicobacter pylori infection, susceptibility to, is related to peptic ulcer disease and atrophic gastritis, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Helicobacter Pylori Infection is IFNGR1 (Interferon Gamma Receptor 1), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Acetylcysteine and Potassium citrate have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and colon, and related phenotypes are helicobacter pylori infection and Synthetic lethal with MLN4924 (a NAE inhibitor)

OMIM : 56 Helicobacter pylori is a microaerophilic, gram-negative bacterium that colonizes the gastric mucosa of approximately 50% of the world's population, and is a primary pathogenic factor in benign and malignant gastroduodenal disease (Warren and Marshall, 1983; Blaser and Parsonnet, 1994). Tomb et al. (1997) reported the complete sequence of the circular genome of H. pylori. The 1,667,867-bp genome contains 1,590 predicted coding sequences (genes). Sequence analysis of these genes indicated that the organism has systems for motility, for scavenging iron, and for DNA restriction and modification. Its survival in acid conditions depends, in part, on its ability to establish a positive inside-membrane potential in low pH. (600263)

Related Diseases for Helicobacter Pylori Infection

Diseases related to Helicobacter Pylori Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 610)
# Related Disease Score Top Affiliating Genes
1 peptic ulcer disease 32.8 S100A8 NFKB1 IL1B GAST CYP2C19 CXCL8
2 atrophic gastritis 31.9 S100A8 MUC6 IL1B GAST CXCL8
3 gastric ulcer 31.9 S100A8 IL1B GAST CYP2C19 CXCL8
4 duodenal ulcer 31.7 S100A8 IL1B GAST CYP2C19 CXCL8 CXCL1
5 microinvasive gastric cancer 31.7 S100A8 MUC6 GAST
6 gastroesophageal reflux 31.6 S100A8 IL1B GAST CYP2C19 CXCL8
7 autoimmune gastritis 31.4 IL1B GAST EGFR
8 gastroduodenitis 31.3 S100A8 GAST
9 peptic esophagitis 31.3 S100A8 IL1B GAST CYP2C19 CXCL8
10 diarrhea 31.3 IL1B GAST EGFR CXCL8
11 chlamydia 31.2 NOD1 IL1B CXCL8
12 duodenum disease 31.2 S100A8 MUC6 GAST
13 peptic ulcer perforation 31.1 S100A8 GAST
14 proteasome-associated autoinflammatory syndrome 1 31.0 IL1B CXCL8 CCL5
15 crohn's disease 31.0 S100A8 NOD1 IL1B CXCL8
16 gastritis 31.0 S100A8 NOD1 MUC6 IL1B GAST CYP2C19
17 esophagitis 30.8 IL1B GAST EGFR CYP2C19 CXCL8 CCL5
18 cholecystitis 30.8 S100A8 MUC6 EGFR
19 mycobacterium fortuitum 30.7 IFNGR1 CXCL8
20 prostatitis 30.7 IL1B CXCL8 CASP3
21 shigellosis 30.7 NOD1 IL1B CXCL8
22 non-alcoholic fatty liver disease 30.6 JUN IL1B CXCL8 CASP3
23 idiopathic neutropenia 30.4 IL1B CCL5 CASP3
24 appendicitis 30.4 S100A8 IL1B CXCL8
25 tonsillitis 30.3 IL1B CXCL8 CXCL1 CASP3
26 salmonellosis 30.3 JUN IL1B IFNGR1
27 gastroesophageal junction adenocarcinoma 30.2 PAK1 IL1B EGFR
28 gastric cancer 30.2 S100A8 PTPN11 PAK1 MUC6 MET JUN
29 gingivitis 30.0 IL1B CXCL8 CCL5
30 neuritis 30.0 IL1B CXCL8 CCL5
31 gastric adenocarcinoma 29.8 S100A8 NFKB1 MET JUN IL1B GAST
32 monocytic leukemia 29.7 JUN IL1B CXCL8 CASP3
33 pertussis 29.6 JUN IL1B CXCL8 CCL5
34 cystic fibrosis 29.3 S100A8 MUC6 JUN IL1B CXCL8
35 eye disease 29.1 JUN IL1B CXCL8 CCL5 CASP3
36 lung disease 29.1 S100A8 MET IL1B IFNGR1 EGFR CXCL8
37 cytomegalovirus infection 29.1 NFKB1 IL1B CXCL8 CHUK CCL5 CASP3
38 arthritis 29.0 JUN IL1B CXCL8 CXCL1 CCL5
39 rheumatoid arthritis 28.8 NFKBIA JUN IL1B CXCL8 CXCL1 CCL5
40 inflammatory bowel disease 28.7 S100A8 NOD1 NFKB1 JUN IL1B IFNGR1
41 t-cell leukemia 28.7 NFKBIA NFKB1 JUN CHUK CASP3
42 pancreatic adenocarcinoma 28.7 MUC6 MET JUN GAST EGFR CXCL8
43 squamous cell carcinoma, head and neck 28.7 NFKBIA MET JUN EGFR CXCL8 CASP3
44 colon adenocarcinoma 28.7 JUN EGFR CXCL8 CASP3
45 pancreatic cancer 28.3 NFKBIA NFKB1 MUC6 MET JUN GAST
46 gastric cancer, hereditary diffuse 11.9
47 gastrointestinal ulceration, recurrent, with dysfunctional platelets 11.1
48 iron metabolism disease 11.0
49 lymphoma, mucosa-associated lymphoid type 11.0
50 deficiency anemia 10.9

Graphical network of the top 20 diseases related to Helicobacter Pylori Infection:



Diseases related to Helicobacter Pylori Infection

Symptoms & Phenotypes for Helicobacter Pylori Infection

Human phenotypes related to Helicobacter Pylori Infection:

31
# Description HPO Frequency HPO Source Accession
1 helicobacter pylori infection 31 HP:0005202

Symptoms via clinical synopsis from OMIM:

56
G I:
helicobacter pylori infection susceptibility

Clinical features from OMIM:

600263

UMLS symptoms related to Helicobacter Pylori Infection:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 CASP3 CHUK CXCL8 IL1B JUN NFKB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 CASP3 CHUK CXCL8 IL1B JUN NFKB1

MGI Mouse Phenotypes related to Helicobacter Pylori Infection:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.28 ADAM10 CASP3 CCL5 CHUK EGFR GAST
2 hematopoietic system MP:0005397 10.27 ADAM10 CASP3 CCL5 CHUK EGFR IFNGR1
3 cellular MP:0005384 10.26 ADAM10 CASP3 CHUK EGFR IFNGR1 JUN
4 homeostasis/metabolism MP:0005376 10.25 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
5 cardiovascular system MP:0005385 10.24 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
6 endocrine/exocrine gland MP:0005379 10.22 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
7 digestive/alimentary MP:0005381 10.15 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
8 mortality/aging MP:0010768 10.13 ADAM10 CASP3 CHUK EGFR GAST IFNGR1
9 craniofacial MP:0005382 10.11 ADAM10 CASP3 CHUK EGFR IL1B MET
10 integument MP:0010771 10.07 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
11 nervous system MP:0003631 9.9 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B
12 neoplasm MP:0002006 9.8 CHUK EGFR GAST IFNGR1 IL1B MET
13 respiratory system MP:0005388 9.56 CASP3 CHUK EGFR JUN MET NFKB1
14 skeleton MP:0005390 9.32 ADAM10 CASP3 CHUK EGFR IFNGR1 IL1B

Drugs & Therapeutics for Helicobacter Pylori Infection

Drugs for Helicobacter Pylori Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Potassium citrate Approved, Investigational, Vet_approved Phase 4
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Titanium dioxide Approved Phase 4 13463-67-7
5
Famotidine Approved Phase 4 76824-35-6 3325
6
Coal tar Approved Phase 4 8007-45-2
7
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
8
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
9
Sodium citrate Approved, Investigational Phase 4 68-04-2
10
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
11
Loperamide Approved Phase 4 53179-11-6 3955
12
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
13
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
14
Azithromycin Approved Phase 4 83905-01-5 55185 447043
15
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
16
Ofloxacin Approved Phase 4 82419-36-1 4583
17
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
18
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
19
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
20
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
21
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
22
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
23
Sulforaphane Investigational Phase 4 142825-10-3, 4478-93-7 5350
24
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
25 N-monoacetylcystine Phase 4
26 Free Radical Scavengers Phase 4
27 Antioxidants Phase 4
28 Antiviral Agents Phase 4
29 Antidotes Phase 4
30 Natriuretic Agents Phase 4
31 Respiratory System Agents Phase 4
32 Expectorants Phase 4
33 diuretics Phase 4
34 Histamine Antagonists Phase 4
35 Histamine H2 Antagonists Phase 4
36
Histamine Phosphate Phase 4 51-74-1 65513
37 Acidophilus Phase 4
38 Hemostatics Phase 4
39 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
40 Chelating Agents Phase 4
41 Citrate Phase 4
42 Anticoagulants Phase 4
43 Calcium, Dietary Phase 4
44 Neurotransmitter Agents Phase 4
45 Bifidobacterium Phase 4
46 Antimalarials Phase 4
47 Trace Elements Phase 4
48 Micronutrients Phase 4
49 Nutrients Phase 4
50 Bile Acids and Salts Phase 4

Interventional clinical trials:

(show top 50) (show all 385)
# Name Status NCT ID Phase Drugs
1 Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication Unknown status NCT02934152 Phase 4 H pylori eradication
2 Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial Unknown status NCT02635191 Phase 4 Tailored Group;Standard group
3 Comparison of the Efficacy of Sequential Therapy and Bismuth Quadruple Therapy in the First Line and Second Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT03156855 Phase 4 14-day sequential therapy;Bismuth quadruple therapy
4 Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection Unknown status NCT02934048 Phase 4
5 Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01906879 Phase 4 triple, quadruple, non-bismuth quadruple therapy
6 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
7 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
8 Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
9 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
10 Helicobacter Pylori Eradication Using a Bismuth Quadruple Therapy Among Asymptomatically Infected Adults in El Paso, Texas: A Pilot Study. Unknown status NCT01335334 Phase 4 bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole
11 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
12 Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
13 Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea Unknown status NCT02108184 Phase 4 Sequential therapy 10 days;Sequential therapy 14 days;Concomitant therapy 10 days;Concomitant therapy 14 days
14 Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Unknown status NCT02552641 Phase 4 Esomeprazole;Amoxicillin;Clarythromycin
15 Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT01607918 Phase 4 D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole);D1-D14: (lansoprazole + clarithromycin + amoxicillin)
16 A Randomized, Double-blind, Placebo-controlled Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice Unknown status NCT03150394 Phase 4
17 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
18 Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment Unknown status NCT03139253 Phase 4 amoxicillin;clarithromycin;tinidazole;levofloxacin;furazolidone;tetracycline;Ilaprazole
19 Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
20 Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections Unknown status NCT01566643 Phase 4 RA5-RACM7;RA3-RACM7;RA7-RACM7
21 Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy. Unknown status NCT01572597 Phase 4 10RAC+acetylcystein;10RAC+metronidazole
22 Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT01537055 Phase 4 levofloxacin-based sequential therapy;levofloxacin-based triple therapy for 10 days
23 Phase 4 Study of Helicobacter Pylori Eradication Therapy Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
24 Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection Unknown status NCT01725906 Phase 4 empirical therapy;Genotypic resistance guided therapy
25 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
26 The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study Completed NCT00885417 Phase 4 Cravit-based sequential therapy
27 Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori Completed NCT01573975 Phase 4 5RA-5RCM;5RA-5RCT;10RCA
28 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
29 The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection Completed NCT01032655 Phase 4 susceptibility test guided sequential therapy
30 Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan Completed NCT01769365 Phase 4 7-day quadruple therapy;10-day sequential therapy;7-day standard triple therapy
31 Canadian North Helicobacter Pylori (CANHelp) Working Group Treatment Trials Completed NCT01967329 Phase 4 Standard Triple;Sequential;Quadruple
32 Phase IV Study Comparing the Duration of Sequential Therapy Completed NCT01042184 Phase 4 Sequential therapy for 14 days;Sequential therapy for 10 days;Triple therapy for 14 days
33 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
34 Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for First-line Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study Completed NCT02483715 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
35 Comparison of 14-day Sequential and Hybrid Therapies for H Pylori Infection Completed NCT01085786 Phase 4 14-day sequential treatment;14-day hybrid treatment
36 A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
37 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
38 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
39 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
40 Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
41 Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori Completed NCT03108287 Phase 4 RAK therapy;RBAK therapy
42 Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection Completed NCT02711176 Phase 4 Nexium;Tinafas;Tavanex;Lanzol;Klacid;Iramox
43 An Interventional, Prospective, Multi-center, Double-blind, Placebo Controlled Postmarketing Study to Evaluate Efficacy and Safety of Normia® Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori Completed NCT01969331 Phase 4
44 The Effect of High Dose Citric on PPI (Proton Pump Inhibitors)Induced False Negative H. Pylori UBT Rates Completed NCT00825630 Phase 4 Lansoprazole (Lanton);Omeprezole (Losec);Pantoprazole(Controloc);Esomeprazole (Nexium)
45 Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection Completed NCT01742429 Phase 4 Proton pump inhibitor;Bismuth subsalicylate;Metronidazole;Tetracycline;Amoxicillin;Levofloxacin
46 Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial Completed NCT04039412 Phase 4 Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
47 Efficacy of High Dose of Amoxicillin And Metronidazole Plus Bismuth For Helicobacter Pylori Treatment In Naive Patients : A Randomized Clinical Trial Completed NCT03557437 Phase 4 Esomeprazole;Amoxicillin, Metronidazole;Bismuth Potassium Citrate
48 A Randomized Controlled Trial of Triple Therapy Versus Sequential Therapy Versus Concomitant Therapy as First Line Treatment for Helicobacter Pylori Infection Completed NCT02092506 Phase 4 10 day triple therapy;10 day sequential therapy;10 day concomitant therapy
49 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
50 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study Completed NCT00854451 Phase 4 omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin

Search NIH Clinical Center for Helicobacter Pylori Infection

Genetic Tests for Helicobacter Pylori Infection

Genetic tests related to Helicobacter Pylori Infection:

# Genetic test Affiliating Genes
1 Helicobacter Pylori Infection, Susceptibility to 29 IFNGR1

Anatomical Context for Helicobacter Pylori Infection

MalaCards organs/tissues related to Helicobacter Pylori Infection:

40
Testes, Liver, Colon, T Cells, B Cells, Heart, Kidney

Publications for Helicobacter Pylori Infection

Articles related to Helicobacter Pylori Infection:

(show top 50) (show all 12386)
# Title Authors PMID Year
1
Genomewide linkage analysis identifies polymorphism in the human interferon-gamma receptor affecting Helicobacter pylori infection. 61 56 6
12516030 2003
2
Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. 61 56
15310903 2004
3
Transmission of Helicobacter pylori infection. 61 56
7672655 1995
4
Expression of a human alpha-1,3/4-fucosyltransferase in the pit cell lineage of FVB/N mouse stomach results in production of Leb-containing glycoconjugates: a potential transgenic mouse model for studying Helicobacter pylori infection. 61 56
7878011 1995
5
Helicobacter pylori infection: genetic and environmental influences. A study of twins. 61 56
8185146 1994
6
Seroprevalence of helicobacter pylori infection in couples. 61 56
2037687 1991
7
Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis. 61 42
31689846 2019
8
A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. 56
22387998 2012
9
A regulatory polymorphism in interferon-gamma receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. 6
19488747 2009
10
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. 56
18488030 2008
11
Helicobacter exploits integrin for type IV secretion and kinase activation. 56
17943123 2007
12
Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. 6
16690980 2006
13
Distinguishing human ethnic groups by means of sequences from Helicobacter pylori: lessons from Ladakh. 56
15051885 2004
14
Protective immunity against Helicobacter is characterized by a unique transcriptional signature. 56
14528007 2003
15
Treatment of Helicobacter gastritis with IL-4 requires somatostatin. 56
14555768 2003
16
Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. 56
12598897 2003
17
Lewis enzyme (alpha1-3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. 56
12730721 2003
18
Helicobacter pylori and gastrointestinal tract adenocarcinomas. 56
11902583 2002
19
Polymorphisms of two fucosyltransferase genes (Lewis and Secretor genes) involving type I Lewis antigens are associated with the presence of anti-Helicobacter pylori IgG antibody. 56
11535550 2001
20
The complete genome sequence of the gastric pathogen Helicobacter pylori. 56
9252185 1997
21
Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. 56
8040281 1994
22
Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. 56
8163943 1994
23
Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. 56
8018146 1993
24
Purification and characterization of the vacuolating toxin from Helicobacter pylori. 56
1587837 1992
25
Unidentified curved bacilli on gastric epithelium in active chronic gastritis. 56
6134060 1983
26
Comparative study of magnifying narrow-band imaging and conventional white light endoscopy in the diagnosis of Helicobacter pylori status after eradication therapy. 42
31725612 2019
27
Helicobacter pylori eradication in dyspepsia: New evidence for symptomatic benefit. 42
31594649 2019
28
MAEL Cancer-Testis Antigen as a Diagnostic Marker in Primary Stages of Gastric Cancer with Helicobacter pylori Infection. 61
30488287 2020
29
Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study. 61
31654635 2020
30
One Step Forward But Room for Improvement in Reducing Risk of Gastric Cancer by Curing Helicobacter pylori Infection. 61
31730770 2020
31
Application of Helicobacter pylori stool antigen test to survey the updated prevalence of Helicobacter pylori infection in Taiwan. 61
31408909 2020
32
Helicobacter pylori infection leads to KLF4 inactivation in gastric cancer through a TET1-mediated DNA methylation mechanism. 61
32017451 2020
33
Previous Helicobacter pylori infection-induced atrophic gastritis: A distinct disease entity in an understudied population without a history of eradication. 61
31680399 2020
34
The relationship of gastric microbiota and Helicobacter pylori infection in pediatrics population. 61
31762120 2020
35
Risk for Colorectal Neoplasia in Patients With Helicobacter pylori Infection: A Systematic Review and Meta-analysis. 61
32032128 2020
36
Potential Impact of Helicobacter pylori Infection on Reflux Disease Sequence: Illuminating the Gap. 61
31851102 2020
37
Inhibitory Effects of β-Caryophyllene on Helicobacter pylori Infection In Vitro and In Vivo. 61
32028744 2020
38
[Helicobacter pylori infection in the HIV + population: a comorbidity to think about]. 61
31933346 2020
39
Development of a novel gene signature in patients without Helicobacter pylori infection gastric cancer. 61
31633246 2020
40
Clostridium difficile-associated disease and Helicobacter pylori seroprevalence: A case-control study. 61
31721371 2020
41
The clinicopathological characteristics and genetic alterations of mucinous carcinoma of the stomach. 61
32015267 2020
42
Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis. 61
31692137 2020
43
Low Prevalence of Helicobacter pylori-Positive Peptic Ulcers in Private Outpatient Endoscopy Centers in the United States. 61
31972622 2020
44
Co-expression of Interleukin-17A molecular adjuvant and prophylactic Helicobacter pylori genetic vaccine could cause sterile immunity in Treg suppressed mice. 61
31629103 2020
45
Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. 61
31787375 2020
46
Preoperative Endoscopic Findings in Veterans Undergoing Bariatric Surgery: Prevalence and Predictors of Barrett's Esophagus. 61
31713148 2020
47
Performance of multiplex serology in discriminating active vs past Helicobacter pylori infection in a primarily African American population in the southeastern United States. 61
31746104 2020
48
Prevalence of Helicobacter pylori infection rate in heterotopic gastric mucosa in histological analysis of duodenal specimens from patients with duodenal ulcer. 61
31264199 2020
49
10-Day Versus 14-Day Quadruple Concomitant Nonbismuth Therapy for the Treatment of Helicobacter pylori Infection: Results From a Randomized Prospective Study in a High Clarithromycin Resistance Country. 61
32028286 2020
50
Statins Were Associated with a Reduced Gastric Cancer Risk in Patients with Eradicated Helicobacter Pylori Infection: A Territory-Wide Propensity Score Matched Study. 61
31792089 2020

Variations for Helicobacter Pylori Infection

ClinVar genetic disease variations for Helicobacter Pylori Infection:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IFNGR1 IFNGR1, -56C-TSNV protective,risk factor 17953

Expression for Helicobacter Pylori Infection

Search GEO for disease gene expression data for Helicobacter Pylori Infection.

Pathways for Helicobacter Pylori Infection

Pathways related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 152)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.32 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
2
Show member pathways
14.02 S100A8 PTPN11 PAK1 NOD1 NFKBIA NFKB1
3
Show member pathways
13.98 PAK1 NFKBIA NFKB1 MET JUN IL1B
4
Show member pathways
13.84 NFKBIA NFKB1 MET JUN IL1B IFNGR1
5
Show member pathways
13.83 PTPN11 NFKBIA NFKB1 MUC6 MET JUN
6
Show member pathways
13.71 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
7
Show member pathways
13.58 PAK1 NFKB1 MET IL1B EGFR CXCL8
8
Show member pathways
13.53 PAK1 NFKB1 JUN EGFR CXCL8 CXCL1
9
Show member pathways
13.47 PTPN11 NOD1 NFKB1 MET IL1B IFNGR1
10
Show member pathways
13.36 PAK1 NFKBIA NFKB1 JUN IL1B IFNGR1
11
Show member pathways
13.34 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
12
Show member pathways
13.2 NOD1 NFKBIA NFKB1 JUN IL1B IFNGR1
13
Show member pathways
13.17 PAK1 NFKB1 MET JUN EGFR CHUK
14
Show member pathways
13.15 PAK1 NFKBIA NFKB1 MET JUN CHUK
15
Show member pathways
13.13 PAK1 NFKBIA NFKB1 JUN EGFR CHUK
16
Show member pathways
13.07 PAK1 NFKBIA NFKB1 JUN CXCL8 CXCL1
17
Show member pathways
13.04 PTPN11 NFKBIA NFKB1 JUN EGFR CHUK
18 13.02 NFKBIA NFKB1 MET JUN IFNGR1 EGFR
19 13 PTPN11 NFKBIA NFKB1 IL1B IFNGR1 CHUK
20
Show member pathways
12.99 NFKBIA NFKB1 JUN IL1B IFNGR1 CXCL8
21 12.97 PAK1 NFKB1 MET JUN IL1B EGFR
22
Show member pathways
12.92 NFKBIA NFKB1 IL1B CXCL8 CHUK CCL5
23
Show member pathways
12.91 NFKBIA NFKB1 JUN CHUK CASP3
24
Show member pathways
12.9 PTPN11 PAK1 NFKBIA NFKB1 MET JUN
25
Show member pathways
12.89 PTPN11 NFKBIA NFKB1 JUN CHUK
26
Show member pathways
12.89 PTPN11 PAK1 NFKB1 MET EGFR CHUK
27
Show member pathways
12.88 PTPN11 NFKBIA NFKB1 MET EGFR CHUK
28
Show member pathways
12.87 NFKBIA NFKB1 JUN IL1B IFNGR1 EGFR
29
Show member pathways
12.86 NFKBIA NFKB1 MET IL1B EGFR CHUK
30
Show member pathways
12.8 PAK1 NFKBIA NFKB1 JUN IFNGR1 CHUK
31
Show member pathways
12.79 PAK1 NFKB1 JUN EGFR CASP3
32
Show member pathways
12.79 PTPN11 PAK1 NFKB1 MET JUN EGFR
33
Show member pathways
12.79 PTPN11 PAK1 NFKBIA NFKB1 IL1B EGFR
34
Show member pathways
12.78 PAK1 NFKBIA NFKB1 JUN IL1B CHUK
35
Show member pathways
12.77 NFKBIA NFKB1 JUN IL1B IFNGR1 CHUK
36 12.74 NOD1 NFKBIA NFKB1 IL1B CHUK CCL5
37
Show member pathways
12.73 PAK1 NFKBIA NFKB1 JUN EGFR CHUK
38
Show member pathways
12.72 PTPN11 NFKBIA NFKB1 JUN CHUK
39
Show member pathways
12.69 PTPN11 PAK1 NFKBIA NFKB1 JUN IL1B
40
Show member pathways
12.66 PTPN11 PAK1 JUN IFNGR1 CASP3
41
Show member pathways
12.65 PTPN11 PAK1 NFKBIA NFKB1 JUN IL1B
42
Show member pathways
12.63 PAK1 NFKBIA NFKB1 MUC6 IL1B CHUK
43
Show member pathways
12.6 NFKBIA NFKB1 JUN GAST EGFR CHUK
44
Show member pathways
12.6 NFKBIA NFKB1 MET JUN IL1B EGFR
45
Show member pathways
12.59 PTPN11 PAK1 NFKBIA NFKB1 JUN CHUK
46
Show member pathways
12.58 PAK1 NFKBIA NFKB1 JUN CHUK
47
Show member pathways
12.57 PTPN11 NFKBIA NFKB1 JUN CHUK
48
Show member pathways
12.56 PAK1 MET JUN EGFR CASP3
49
Show member pathways
12.56 PTPN11 NFKBIA NFKB1 MET CHUK
50
Show member pathways
12.55 PAK1 NFKBIA NFKB1 JUN CHUK

GO Terms for Helicobacter Pylori Infection

Cellular components related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 S100A8 NFKB1 MUC6 MET IL1B GAST
2 I-kappaB/NF-kappaB complex GO:0033256 8.62 NFKBIA NFKB1

Biological processes related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 NOD1 NFKB1 MET IL1B IFNGR1 GAST
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.2 NFKBIA NFKB1 MET JUN IL1B EGFR
3 positive regulation of transcription, DNA-templated GO:0045893 10.09 NFKBIA NFKB1 JUN IL1B EGFR CHUK
4 immune response GO:0006955 10.07 IL1B CXCL8 CXCL1 CHUK CCL5
5 intracellular signal transduction GO:0035556 10.06 NOD1 EGFR CXCL8 CXCL1 CASP3
6 apoptotic process GO:0006915 10.04 S100A8 PAK1 NOD1 NFKBIA NFKB1 IL1B
7 MAPK cascade GO:0000165 9.97 PAK1 MET IL1B EGFR CCL5
8 positive regulation of cell migration GO:0030335 9.97 PAK1 IL1B EGFR CCL5 ADAM10
9 cellular response to lipopolysaccharide GO:0071222 9.93 NFKB1 IL1B CXCL8 CXCL1
10 Fc-epsilon receptor signaling pathway GO:0038095 9.93 PAK1 NFKB1 JUN CHUK
11 chemotaxis GO:0006935 9.92 S100A8 CXCL8 CXCL1 CCL5
12 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 PTPN11 NOD1 JUN EGFR CCL5
13 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.88 PAK1 NFKB1 MUC6 CHUK
14 cellular response to interleukin-1 GO:0071347 9.86 NFKB1 CXCL8 CCL5
15 wound healing GO:0042060 9.86 S100A8 PAK1 EGFR CASP3
16 liver development GO:0001889 9.85 MET JUN EGFR
17 positive regulation of cell growth GO:0030307 9.85 S100A8 EGFR ADAM10
18 chemokine-mediated signaling pathway GO:0070098 9.85 CXCL8 CXCL1 CCL5
19 cellular response to organic cyclic compound GO:0071407 9.84 IL1B CCL5 CASP3
20 response to organic substance GO:0010033 9.84 PAK1 JUN CHUK CASP3
21 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.83 NFKBIA NFKB1 CHUK
22 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 NOD1 IL1B EGFR
23 positive regulation of inflammatory response GO:0050729 9.83 S100A8 NFKBIA IL1B EGFR
24 positive regulation of interleukin-6 production GO:0032755 9.82 PTPN11 NOD1 IL1B
25 positive regulation of smooth muscle cell proliferation GO:0048661 9.82 JUN EGFR CCL5
26 response to cytokine GO:0034097 9.81 NFKB1 JUN CCL5
27 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 S100A8 NOD1 NFKB1 IL1B CHUK
28 cellular response to reactive oxygen species GO:0034614 9.79 JUN EGFR CHUK
29 cellular response to cadmium ion GO:0071276 9.78 JUN EGFR CHUK
30 cellular response to mechanical stimulus GO:0071260 9.78 PTPN11 NFKB1 IL1B EGFR
31 response to tumor necrosis factor GO:0034612 9.77 CCL5 CASP3 ADAM10
32 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 NFKBIA IL1B CCL5
33 cellular response to tumor necrosis factor GO:0071356 9.77 NFKBIA NFKB1 CXCL8 CHUK CCL5
34 interleukin-1-mediated signaling pathway GO:0070498 9.72 NOD1 NFKBIA NFKB1 IL1B CHUK
35 hepatocyte growth factor receptor signaling pathway GO:0048012 9.69 PAK1 MET
36 negative regulation by host of viral transcription GO:0043922 9.69 JUN CCL5
37 neutrophil activation GO:0042119 9.68 CXCL8 CCL5
38 neutrophil chemotaxis GO:0030593 9.65 S100A8 IL1B CXCL8 CXCL1 CCL5
39 astrocyte activation GO:0048143 9.63 IL1B IFNGR1 EGFR
40 response to lipopolysaccharide GO:0032496 9.63 S100A8 NFKBIA JUN IL1B CHUK CASP3
41 response to muscle stretch GO:0035994 9.61 NFKBIA NFKB1 JUN
42 cytokine-mediated signaling pathway GO:0019221 9.5 PTPN11 IL1B IFNGR1 CXCL8 CXCL1 CCL5
43 inflammatory response GO:0006954 9.23 S100A8 NOD1 NFKB1 IL1B CXCL8 CXCL1

Molecular functions related to Helicobacter Pylori Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.8 NOD1 NFKB1 JUN CHUK CCL5 ADAM10
2 identical protein binding GO:0042802 9.7 NOD1 NFKBIA NFKB1 MET JUN EGFR
3 protein binding GO:0005515 9.58 S100A8 PTPN11 PAK1 NOD1 NFKBIA NFKB1
4 cytokine activity GO:0005125 9.56 IL1B CXCL8 CXCL1 CCL5
5 chemokine activity GO:0008009 9.13 CXCL8 CXCL1 CCL5

Sources for Helicobacter Pylori Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....